Plato Investment Management Ltd Sells 217 Shares of Illumina, Inc. (NASDAQ:ILMN)

Plato Investment Management Ltd trimmed its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,578 shares of the life sciences company’s stock after selling 217 shares during the quarter. Plato Investment Management Ltd’s holdings in Illumina were worth $1,821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of ILMN. Empowered Funds LLC lifted its holdings in Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares during the period. Bank of Stockton lifted its stake in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after purchasing an additional 80 shares during the period. Caprock Group LLC lifted its stake in shares of Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares during the period. Stephens Inc. AR lifted its stake in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after purchasing an additional 90 shares during the period. Finally, Moors & Cabot Inc. lifted its stake in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after purchasing an additional 95 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

NASDAQ ILMN opened at $84.20 on Tuesday. The stock has a 50-day simple moving average of $122.36 and a two-hundred day simple moving average of $132.81. The firm has a market capitalization of $13.34 billion, a P/E ratio of -10.96, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a fifty-two week low of $83.79 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and lowered their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research note on Friday. Finally, Citigroup cut Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $155.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.